Akeso's Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China Akeso, Biopharma announced that the Center for Drug Evaluation of the China National Medical Products Administration has granted Breakthrough Therapy Designation for Ivonescimab combined with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma patients who failed to respond to prior PD-1 inhibitor combined with platinum-based doublet chemotherapy. Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting Innovent Biologics, Inc. presented the updated results of IBI351 from a phase Ia clinical trial at the 2022 Chinese Society of Clinical Oncology Annual Meeting. SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969 SK Biopharmaceuticals announced that the state-run Korea Drug Development Fund has decided to support and finance the company's development of SKL27969, which is being evaluated as potential treatment for patients with advanced solid tumors, widening SK Biopharmaceuticals' area into oncology. HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China HUTCHMED Limited announces initial results from FRUTIGA, a Phase III study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction adenocarcinoma. Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years 11/13/2022 Ascendis Pharma A/S announced positive topline results from the ACcomplisH Trial, its Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial evaluating the safety and efficacy of once-weekly TransCon CNP compared to placebo in children with achondroplasia aged 2 to 10 years old. Lupus Foundation of America Recognizes Scientists for Exceptional Contributions in Lupus Research 11/13/2022 The Lupus Foundation of America is pleased to honor two leading scientists for their notable contributions to lupus research at the 2022 Evelyn V. Hess Reception held during the American College of Rheumatology convergence 2022 meeting this evening in Philadelphia, PA. Telix Acquires Optimal Tracers 11/13/2022 Telix Pharmaceuticals Limited announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials. Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis 11/13/2022 Sofusa®, a wholly-owned division of Sorrento Therapeutics, announced that it will host a virtual Key Opinion Leader panel discussion titled “Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System” to be held on Thursday, November 17, 2022 at 11:30 AM EST. Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting 11/13/2022 Ionis Pharmaceuticals, Inc. presented positive results from a Phase 2 open-label extension study evaluating the safety and efficacy of its investigational antisense medicine, donidalorsen, in patients with hereditary angioedema, a rare and devastating inflammatory disease. Study Examines Total Knee Replacement in Patients Under 21 11/13/2022 A new study from researchers at Hospital for Special Surgery has evaluated trends in the use of total knee arthroplasty in patients under 21 in the United States. HSS Research Uncovers How UV Light Triggers Immune Activation and Disease Flares in Lupus 11/13/2022 After sun exposure, people with systemic lupus erythematosus frequently develop skin rashes, which often are accompanied by a flare of their overall disease. Study Finds Chronic-Pain Management, Falls and Limited Access to Care Are Critical Issues Among Medically Underserved 11/13/2022 To improve the health of a community, the first step is to identify its most pressing needs. Sparrow Pharmaceuticals Presents Pharmacology Data on SPI-62 at American College of Rheumatology Convergence 2022 11/13/2022 Sparrow Pharmaceuticals presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology Convergence 2022 meeting. Participation Doubles After Lupus Support Group at HSS Transitions to Virtual Format During Pandemic 11/12/2022 A study at Hospital for Special Surgery highlights the success of a lupus peer support and education group that transitioned to a virtual format during the pandemic. HSS Rheumatologists, Social Worker Honored by American College of Rheumatology 11/12/2022 The American College of Rheumatology and the Association of Rheumatology Professionals have honored two rheumatologists and a social worker at Hospital for Special Surgery with prestigious awards.